Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (1447)	2/7/2003 4:57:04 AM
From: Icebrg	Read Replies (1) \| Respond to of 3158

>>No one ascribed any value to Remicade which is a lot bigger than Embrel, even though no one notices this fact. >> This is due to the fact, that in a place like this, most of the interest is not directed towards a drug per se, but more to the transformation of the value of its sponsor, if its development should turn out to be successful. I am sure that Embrel, having been swallowed by Amgen, will soon start to be perceived as un-exciting as Remicade already is.

To: Robohogs who wrote (1447)	2/7/2003 9:47:29 AM
From: rkrw	Read Replies (1) \| Respond to of 3158

Did cnto own remicade outright or was it partnered with jnj early on? Definite great buy by jnj on that one. cnto would have been a monster stock. Note a scios merger is far from assured.